CARsgen Therapeutics Holdings Limited (02171) announced its Next Day Disclosure Return on 23 October 2025, indicating that its issued share count remained at 577,934,314 shares before and after the relevant events. The closing balance of issued shares (excluding treasury shares) as of 23 October 2025 remained unchanged at 577,934,314.

According to the filing, repurchases for cancellation but not yet cancelled took place on 21 and 23 October 2025. On 21 October 2025, 250,000 shares were repurchased at HKD 17.08. On 23 October 2025, 205,000 shares were repurchased at HKD 16.58.

The repurchase report also noted a buyback of 205,000 shares on 23 October 2025 at a price between HKD 16.47 and HKD 16.7, totaling HKD 3,398,174.92. The repurchase mandate had been granted on 22 May 2025, authorizing up to 57,543,590 shares for buyback. As of this filing, the company had repurchased 455,000 shares, representing 0.0791% of its issued shares at the time the mandate was approved.

No new issued shares or on-market sales of treasury shares were reported during this period. The company emphasized that the repurchases detailed in the disclosure were conducted in accordance with applicable rules and regulations.